Letters
Dementia drug funding in France
Dementia drugs should be reimbursed for the sake of responders
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m651 (Published 20 February 2020) Cite this as: BMJ 2020;368:m651
- Tobias Damgaard, pharmacist
- Pharmaceutical Department, Region Kalmar County, Box 601, 391 26 Kalmar, Sweden
- tobias.damgaard{at}regionkalmar.se
I am surprised to hear of the French minister of health’s decision to stop funding dementia drugs.1 The reasoning is incomplete for several reasons.
Firstly, pharmacological treatments for dementia are not curative and cannot substitute non-pharmacological interventions. Caregivers know this. In Sweden, healthcare personnel already work hard to develop and integrate non-pharmacological interventions regularly; withdrawing reimbursement would not promote …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.